Article Text

Download PDFPDF
Plasma cell leukaemia with t(11;14) not responsive to venetoclax
  1. Mohammed Isaac Abu Zaanona1 and
  2. Priyank Patel2
  1. 1Internal Medicine, Carle Foundation Hospital, Urbana, Illinois, USA
  2. 2Department of Hematology & Oncology, Carle Foundation Hospital, Urbana, Illinois, USA
  1. Correspondence to Dr Mohammed Isaac Abu Zaanona; mabuzaanona{at}


A 70-year-old man with medical history of IgG kappa multiple myeloma, initially diagnosed in 2017, underwent induction therapy with carfilzomib, lenalidomide and dexamethasone followed by autologous haematopoietic stem cell transplantation. Nine months following transplant, disease relapsed in the form of plasma cell leukaemia. Fluorescent in situ hybridisation of malignant plasma cells revealed t(11;14). A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. Unfortunately, the disease was primary refractory, and after further ineffective therapies, the patient did not have a successful outcome.

  • haematology (incl blood transfusion)
  • oncology
  • chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors MIAZ and PP were involved in patient care, data acquisition, and drafting of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.